Member Info for CauldStream7

It is amazing how negative the comments are about this RNS.

It is surely very good news that a CRO has been appointed and that Avion are on board. The trial is live and work is on-going on the selection process of patients who will be taking part in the trial. It is clear that behind-the-scenes work has been taking place on animal trials using much higher levels of Lupuzor which will now inform the new Phase 3 Lupuzor trial. It is a misunderstanding on the part of many commentators that Simbec-Orion are sitting on their hands. They are not, they have been given the go-ahead to go ahead with the Trial. No doubt it will take some weeks to choose the patients for the Trial in the countries where it is being conducted, and when the first of them will be treated with Lupuzor.

Other prep. work is surely being undertaken, for example to ensure that sufficient amounts of Lupuzor have been manufactured for the trial.

I therefore feel confident that by this time in 2024 we shall be in a much better place with regard to Lupuzor.

Wildbunch:

Thanks for your insightful comments about the near to mid-term future of Imm, Lupuzor and P140 treatment of CIDP, etc. Also your comments about Dr Reilly's appointment to the Board; he certainly seems to have the appropriate experience and skills to help IMM to establish partnerships with other pharma companies to finance trials and to commercialise Imm's future drug candidates.

I'm waiting with bated breath to see what next week brings by way of an important RNS from IMM.

Dallo:

Thanks for that. But remember Tim is only the mouthpiece. It's the pharma experts behind the scenes, especially the ones who represent Avion, who will write his script and decide when it is appropriate to pronounce it.

Flash/Dallo.

Thanks for your insights into the rapid oscillations in the IMM share price. I am still averaging down from the earlier heights I bought IMM shares 5 and more years ago. I don't mind who the sellers are who make this possible.

But surely there will come a time, perhaps after the next RNS, when it will pay Lanstead to let the upward pressure out of the bottle and let the price rip up. They have a huge shareholding in IMM and it is surely the case that the gain they will make from the share appreciation will far outweigh the benefit they obtain from suppressing the SP and having to pay out lower instalments on their loan agreement with IMM. I think this is only a matter of time - perhaps a very short time.

LLofL.

There is no sign that Avion has chucked in the towel; why would they? So I think that the SP is highly unlikely to trade below 1p.

MavD:

I agree; an RNS either this week of next. Avion and IMM will be doing their utmost to issue one before Christmas.

And I have a feeling that by the end of this year we will say goodbye to trading below 2p. I'm very glad that I concluded buys at below 2p during the past few weeks. A bargain price which I believe will not be repeated beyond this month.

Nolupus:

Shares in issue - good point. But 25 times as many now compared with then? Where do I go to find out?

Nolupus:

Thanks for your response. I agree that there might be some justification for the difference between the price of 180p in 2018 just before the result of the first Lupuzor Phase 3 trial, and the price now.

But what I find strange is the contrast between the SP of 48.5p in 2013 when I bought my first IMM shares and the price now. In 2013, Lupuzor was still some way from entering its Phase3 trial and IMM had no other drug candidate close to the same stage of development. This is in contrast to now. We have the P140 formulation to treat CIDP which is at the same advanced stage of FDA testing as Lupuzor. Plus there are the 2 other anti-infectives at an earlier stage of testing. Moreover, IMM now has a commercial partner, Avion, which is willing to commit to a much larger budget for the new Lupuzor trial. That advantage was not on the horizon for IMM in 2013. So how come its SP then, was 25 times higher than it is now? I still don't get it.

It's strange that 10 years ago, I paid 25 times what I'm paying now per IMM share. Can there be a rational justification for this huge difference?

Dallo/wildbunch

Your reference to being long term holders of IMM stock, made me look at my holdings. I found that my first purchase was on 13/8/2013, ie. more than a decade ago. I bought 10,000 @ 48.50.

I never thought then that I would have to wait and wait for so long before I knew whether this would turn out to be a wise investent or not. And I'm still none the wiser! But I've averaged down in the past 2 years and now into single figures, price-wise, but at the cost of even more exposure to this share.

Wildbunch:

I've been trying to guess what EMH stands for. I presume not ExtraMarital(H)affairs. Can you please explain to this ignoramus?

Wildbunch:

Your hypothesis is quite convincing.

Lisa has been urging me to be patient just as she is having to be patient with her team. At the same time she says that everyone is on the same page within IMM/Avion and know it is important to make an announcement to shareholders asap.

This does not suggest a crisis, let alone the likelihood that Avion is about to quit the deal. As you say, perhaps the opposite is the truth.

Nolupus:

Yes, how about the deal with Avion to finance the new Phase2/3 Lupuzor trial?

Llol:

That's no reply to Pokerchips. It's up to you to produce the evidence of Tim's false promises, not Poker's job to sieve through your many posts.

MM:

Good to hear that you are receiving excellent care from your health professionals. Good luck for the future.

Re IMM and Tim. How can you possibly tell whether he is taking private shareholders for a ride? How can you know whether Tim cares about shareholders and lupus sufferers? Perhaps he is powerless to dictate the pace at which the Avion and IMM research teams are working towards final agreement on the details of the Lupuzor trial. Give the guy a break and believe that he and other leaders of both companies are acting in good faith towards us and lupus sufferers. I'm just a private shareholder like you, but I accept the assurances from Lisa Baderoon, who liaises with people like us on behalf of IMM, that the research teams of both companies are working collaboratively to achieve the best outcome for Lupuzor in its final Phase 2/3 trial. There is very little that Tim can or should do in all this, except to update us on what is going on.

Mystic Mike:

I am really sorry to hear of your struggle with cancer. Please take comfort that there will be many on the platform who will join with me in wishing you all the best with your treatment and hoping that your treatment will return you to good health. Much more important than the share price of IMM. Naturally we all hope Lupuzor will turn out to be a success but it's not the be-all and end-all of life

Wildbunch:

I agree, it's much better to contact IMM directly than to indulge in histrionics like MysticMike and others of his ilk. I have always found that Lisa answers my queries within the boundaries that obviously stop her from revealing insider information. I believe that she is behaving in good faith when she says that the senior teams of IMM and Avion know the importance of bringing news to the public about Lupuzor and IMM's other drug candidates as soon as possible. The problem is that it takes more time to agree the details and protocols of the next Lupuzor Trial than I and obviously many other private investors had reckoned on.

My hope and expectation is that there will be a major announcement before Christmas.

Lambo222;

You are mistaken when you say of Avion and IMM ""they have never conducted trials before". Avion has considerable experience of bringing new drugs to market via FDA trials and IMM has the experience of its previous Phase 3 Lupuzor trial which failed but at least gave the company some insight into the likely pitfalls of any new trial they participate in. I suggest that the time it's taking to announce the start of the new Phase2/3 trial of Lupuzor is due to a desire to dot all the "i's" and cross every "t's" to ensure as far as possible that this time the Lupuzor trial will be successful.

But I presume that we'll all be a lot wiser shortly when IMM at last releases a new RNS on this.

Machin:

I would not say you are crazy. It all depends on whether you can afford to lose your investment. And tho' I sometimes feel depressed with the painfully slow progress being made in getting the Lupuzor Phase 2/3 Trial started and by the likewise slow progress on the CIDP trial and the ROW licence to develop Lupuzor, I still think that the purchase of IMM shares at the present cheap as chips price will come good, BIG time.

But I am getting tired of waiting!

Oscar:

It's 10 days since your interesting comments on the strategic alliance between Avion and IMM leading up to the next Lupuzor trial.

Tim McC has always promised that the next Lupuzor trial would would start in H2 of this year. We are now getting awfully close to the end of this period. In your opinion, are there any signs that his promise will be fulfilled?